Mallinckrodt’s spending on political donations and lobbying comes as the drug industry as a whole beefs up its Capitol Hill presence.
NYS Entity Status
NYS Filing Date
APRIL 23, 2013
NYS DOS ID#
NYS Entity Type
DOMESTIC BUSINESS CORPORATION
2013 - KWANGDONG PHARMACEUTICAL USA INC.
AROUND THE WEB
- A Drug Maker Spends Big in Washington to Make Itself Heard
By JAY HANCOCK, ELIZABETH LUCAS and SYDNEY LUPKIN - Friday Jul 21, 2017
- Considering the Side Effects of Drugmakers’ Money-Back Guarantees
By KATIE THOMAS and CHARLES ORNSTEIN - Monday Jul 10, 2017
The Trump administration is considering encouraging lowering drug costs through outcome-based contracts, but there is little evidence the approach works.
- Martin Shkreli, ‘Pharma Bro,’ Prepares for Trial: ‘I’m So Innocent’
By STEPHANIE CLIFFORD - Thursday Jun 22, 2017
The former hedge fund manager, vilified by the public and politicians after increasing the price of a prescription drug, is facing eight counts of securities and wire fraud.
- Insurers Battle Families Over Costly Drug for Fatal Disease
By KATIE THOMAS - Thursday Jun 22, 2017
The case of Exondys 51 poses emotionally charged issues for families of young boys with a rare illness, who are fighting companies to get coverage for an expensive drug approved on a lower bar of proof.
- The Strange Case of Martin Shkreli Is Wrapping Up
By STEPHANIE CLIFFORD - Wednesday Jul 26, 2017
An unusual trial has featured victims who actually made money and defense lawyers who paint their client as an erratic misfit and want more victims to testify.
- For Parkinson’s, Two New Drugs Coming As Prevail Gets Started in NY
By Ben Fidler - Wednesday Aug 9, 2017
A drug that actually slows or reverses the brain damage inflicted by Parkinson’s disease, rather than just alleviates its often debilitating symptoms, remains elusive. But Prevail Therapeutics, a startup just launched in New York, has become the latest to try. This morning, the Silverstein Foundation, a nonprofit organization formed by OrbiMed partner Jonathan Silverstein, announced […]